findmyKOL
Clinical trialNCT04062266Active, not recruitingPhase 2Interventional

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

SponsorM.D. Anderson Cancer CenterEnrollment50Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionFLT3 Gene MutationHematologic and Lymphocytic DisorderMinimal Residual Disease PersistenceTherapy-Related Acute Myeloid Leukemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Venetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Sept 2019
Primary completion
31 Oct 2030
Completion
31 Oct 2030
Last update posted
8 Jun 2026
Registered enrollment
50
Registry id
NCT04062266
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.